Company: LENZ
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001193125-25-100630
Chunk: 30

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 30
---
 of December 31, 2024, Mr. McCollum holds outstanding options to purchase 27,000 shares. |

| (5) | As of December 31, 2024, Ms. Thunen holds outstanding options to purchase 27,000 shares. |

| (6) | As of December 31, 2024, Dr. Scheiner holds outstanding options to purchase 27,000 shares. |

| (7) | Resigned from the board of directors on March 21, 2024, effective as of the effective time of the Merger. |

| (8) | Dr. Porteus received compensation from Graphite under a consulting agreement. |

-16-

Insider Trading Policy We have adoptedan insider trading policy governing the purchase, sale, and/or other dispositions of our securities and those of public companies in which we have a business relationship by our directors, executive officers, employees and independent contractors, contingent workers and consultants, that we believe is reasonably designed to promote compliance with insider trading laws, rules and regulations, and the exchange listing standards applicable to us. It is our policy that any transactions in LENZ securities by the company itself shall be in full compliance with insider trading laws, rules and regulations. -17-

<div align='center'>**PROPOSAL NO. 1:

ELECTION OF CLASS III AND CLASS I DIRECTORS**</div>

**Our board of directors currently consists of seven directors and is divided into three classes with staggered three-year terms. At the annual meeting, two Class III directors will be elected for a two year-term and two Class I directors will be elected for a three-year term, each to succeed the same class whose term is then expiring. Each director’s term continues until the expiration of the term for which such director was elected and until such director’s successor is elected and qualified or until such director’s earlier death, resignation or removal.

Nominees

Our nominating and governance committee has recommended, and our board of directors has approved, Kimberlee C. Drapkin and Zach Scheiner as nominees for election as Class III directors at the annual meeting and Frederic Guerard and James McCollum as nominees as Class I directors at the annual meeting. If elected, each of Ms. Drapkin and Dr. Scheiner will serve as a Class III director until the 2027 annual meeting of stockholders and Dr. Guerard and Mr. McCollum will serve as a Class I director until the